New data for simeprevir will be presented at EASL's International Liver Congress™ 2017

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new clinical data for simeprevir, an NS3/4A protease inhibitor for the treatment of hepatitis C virus infection, will be presented by our partner Janssen Sciences Ireland UC (Janssen) in conjunction with The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April.

A total of four presentations will be made, including one oral presentation. The presentations will cover preclinical and clinical data on the triple combination of simeprevir, odalasvir and AL-335, as well as data on the efficacy, safety and tolerability of simeprevir used as a component of various combination therapies in a number of different adult patient populations.

Data presented at the International Liver Congress™ 2017 include:

Oral Presentation:
Abstract PS-153
Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis.
Authors: Ed Gane, Catherine Stedman, Matthew McClure, David Apelian, Chris Westland, Jennifer Vuong, Megha Patel, Thomas Kakuda, Sushmita Chanda, Lawrence Blatt, Leo Beigelman, David Smith, John Fry

Poster Presentations:
Abstract FRI-276
In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir.
Authors: Leen Vijgen, Bart Fevery, Andreas Jekle, Kenneth Shaw, Hua Tan, Oliver Lenz, Julian Symons, Sandra De Meyer

Abstract THU-281
Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies.
Authors: Fiona Marra, Christoph Höner zu Siederdissen, Saye Khoo, Markus Cornberg, Michael Schlag, Sivi Ouwerkerk-Mahadevan, Ceyhun Bicer, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer, David Back

Abstract FRI-249
Efficacy and safety of simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy.
Authors: John Dillon, Stefan Mauss, Catherine Nalpas, Ceyhun Bicer, Michael Schlag, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer

Details of all presentations for The International Liver Congress™ 2017 are available at: http://www.easl.eu/.

For further information, please contact:
Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
**About Medivir**

Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.